Introduction
============

Infections caused by antibiotic-resistant pathogens cause substantial morbidity and mortality globally \[[@b1-kjp-2018-07290]\]. Inappropriate use and overuse of antibiotics are the most important factors causing increased bacterial resistance, thus affecting patient outcomes and the spread of infections caused by multidrug-resistant organisms \[[@b2-kjp-2018-07290]\]. Antibiotics can be overprescribed in everyday clinical practice; for instance, antibiotics may be prescribed for conditions in which antibiotics are not indicated, such as respiratory viral infections \[[@b3-kjp-2018-07290]\]. In addition to the use of unnecessary antibiotics, the inappropriate use of broad-spectrum agents when narrower-spectrum agents are indicated is common \[[@b4-kjp-2018-07290]\].

In Korea, antibiotic overuse and the burden of antibiotic resistance have become important public health issues in recent years. Antibiotic use among children should receive particular attention because of the frequency of community-associated infections among this age group, their longer life expectancies, and the elevated risk of exposure to antibiotic-resistant pathogens in cases of drug control \[[@b5-kjp-2018-07290]\]. Professional societies have encouraged judicious antibiotic use, focusing on decreasing the inappropriate use of broad-spectrum agents in both inpatient and outpatient settings \[[@b6-kjp-2018-07290]\]. However, descriptive data to estimate antibiotic use is important for evaluating the changes driven by policies. In this review, we aim to describe the patterns of antibiotic prescription and to evaluate recent trends in antibiotic use among children in Korea.

Concerns of antibiotic resistance
=================================

According to World Health Organization (WHO) data from 2014, the prevalence of resistant organisms is considerably high in Korea; the resistance rate of *Staphylococcus aureus* to methicillin ranges from 57.7% to 73.0%, while that of *Escherichia coli* to third-generation cephalosporin ranges from 23.9% to 28.0% \[[@b7-kjp-2018-07290]\]. The prevalence of antibiotic resistance in Korea varies across pathogens and collection periods, but is comparable to that in neighboring Asian countries. [Fig. 1](#f1-kjp-2018-07290){ref-type="fig"} depicts a comparison of the general prevalence of antibiotic resistance in Korea and other Asian countries. Among clinical isolates of *Streptococcus pneumoniae* from 11 Asian countries, between 2000 and 2001, isolates from Korea showed the second highest prevalence of penicillin resistance (54.8%), after those from Vietnam (71.4%), followed by isolates from Hong Kong (43.2%) and Taiwan (38.6%) \[[@b8-kjp-2018-07290]\]. Among *E. coli* isolates from urinary tract infections, 20% of the isolates from Korea were extended-spectrum beta lactamase-producers, with the country ranking seventh in this regard among Asian countries \[[@b9-kjp-2018-07290]\]. The prevalence of methicillin resistance in hospitalacquired *S. aureus* isolates was also high in Korea, at 77.6% after only Sri Lanka (86.5%), and followed by that in Vietnam (74.1%), Taiwan (65.0%), and Thailand (57.0%) \[[@b10-kjp-2018-07290]\].

Global antibiotic consumption
=============================

Globally, antibiotic consumption has been low in high-income countries, whereas it has been disproportionally high in low- and middle-income countries. One study that reviewed trends in antibiotic consumption in 71 countries between 2000 and 2010 showed that antibiotic consumption was stable or had moderately decreased in high-income countries \[[@b11-kjp-2018-07290]\]. According to a more recent study that extended the analysis to 2015, the consumption rates for cephalosporins, quinolones, and macrolides decreased in high-income countries and increased in low- and middle-income countries \[[@b12-kjp-2018-07290]\]. In both studies, Korea showed increasing trends of antibiotic consumption and had the highest consumption rate among highincome countries. Cross-sectional data presented in 2014 by the Organisation for Economic Co-operation and Development (OECD) suggested that the rate of antibiotic consumption in Korea is 31.7 defined daily doses per 1,000 inhabitants/day (DID), while the rate of average use in OECD countries is 20.5 DID ([Fig. 2](#f2-kjp-2018-07290){ref-type="fig"}) \[[@b13-kjp-2018-07290]\]. Countries with comparable population sizes and economies, such as Spain and Italy, had lower DID than did Korea, at 21.6 and 27.8 DID, respectively.

A brief summary combining OECD data on antibiotic consumption with WHO data on antibiotic resistance rates is provided in [Fig. 3](#f3-kjp-2018-07290){ref-type="fig"}. The prevalence of resistant organisms by proportion is generally correlated with the magnitude of antibiotic consumption in different OECD countries. Small or moderate correlation was noted for *E. coli* resistance to fluoroquinolones (*R*^2^=0.289), Klebsiella pneumoniae resistance to third-generation cephalosporins (*R*^2^=0.220), and methicillin-resistant *Staphylococcus aureus* (MRSA) (*R*^2^=0.316). Korea was largely at the higher end for both antibiotic consumption and prevalence of resistant organisms.

Globally, antibiotics are the most commonly prescribed class of medication among children. A study from the United States (US) that used an outpatient prescription drug utilization program showed that amoxicillin was the most frequently dispensed prescription for infants and children in 2010 (n=18,292,768), followed by azithromycin (n=10.171,046), albuterol (n=7,343,063), and amoxicillin-clavulanate (n=4,454,926) \[[@b14-kjp-2018-07290]\]. Systemic antibiotics were the most frequently dispensed medications for children, accounting for 24% to 27% of all prescriptions between 2002 and 2010; however, the number of prescriptions decreased by 14% during this period. Cefdinir---a second-generation cephalosporin---and cephalexin---a first-generation cephalosporin---were the only prescribed cephalosporins studied in this investigation.

Over the last two decades, professional societies such as the American Academy of Pediatrics have addressed the issue of antibiotic overuse and the development of drug-resistant organisms by educating parents and promoting evidence-based guidelines among practitioners \[[@b15-kjp-2018-07290]\]. Their efforts have been supported by the government: former US president Barack Obama released an executive order on combating antibiotic-resistant bacteria \[[@b16-kjp-2018-07290]\]. A variety of initiatives from the medical community also promote the appropriate use of antimicrobial drugs and the prevention of antibiotic-resistant infections.

The Korean context
==================

The recent trends in Korean antibiotic consumption at the national level have been evaluated in a few studies. The first study used National Health Insurance claims data collected through the Health Insurance Review and Assessment (HIRA) service to quantify and analyze patterns of total systemic antibiotic prescriptions filed in Korea from 2008 to 2012 \[[@b17-kjp-2018-07290]\]. The results showed that the total consumption of antibiotics increased from 21.68 DID in 2008 to 23.12 DID in 2012. Penicillins were the most commonly used antibiotics (4.52 DID), followed by second-generation cephalosporins (4.47 DID) and macrolides (3.32 DID). There was a significant increase in the consumption of third-generation cephalosporins, carbapenems, and glycopeptides (*P* \< 0.001). The study also investigated the differences in these trends among age groups. Compared to adolescents and adults, children had higher rates of penicillin, macrolide, and third-generation cephalosporin consumption (2.2-, 2.0-, and 2.6 fold greater, respectively). The second study also used HIRA claims data for a similar study period (2007--2014), but included additional information on trend changes for antibiotic classes in different age groups \[[@b18-kjp-2018-07290]\]. Children aged younger than 6 years had the highest level of use (59.21 DID) in 2014, and showed an increasing trend each year, consistent with previous findings. The prescription rate of extended-spectrum penicillins and third- and fourth-generation cephalosporins showed an increasing trend, while the prescription rate of first- and second-generation cephalosporins seemed to have declined ([Fig. 4](#f4-kjp-2018-07290){ref-type="fig"}).

A cross-national analysis was conducted from cohorts from 6 countries, including Germany, Italy, Korea, Norway, Spain, and the US, between 2008 and 2012 \[[@b19-kjp-2018-07290]\]. This study showed that Korea had the highest rate of antimicrobial consumption among children, with 3.41 prescribed courses per child per year during the first 2 years of life, as compared to 1.4--1.6 in Italy, 1.5 in Spain, 1.1 in the US, 1.0 in Germany, and 0.5 in Norway. The finding suggests that an average toddler in Korea is prescribed antibiotics at a prescription rate 7.5 fold higher than that in Norway. Moreover, higher proportions of broad-spectrum agents are used in Korea. The study found that among all pediatric antimicrobial prescriptions in Korea, 9.8% were first-line penicillins (likely amoxicillin), whereas in Norway and Germany, 64.8% and 39.6% were first-line penicillins, respectively. Multiple factors may affect the choice of antibiotics in the treatment of children with possible bacterial infection. In Korea, which has higher resistance rates, healthcare providers are more inclined to prescribe antibiotics with broader coverage. However, this practice exerts constant selective pressure due to broad-spectrum antibiotics, which may cause a further increase in the resistance rate.

One recent study that used National Patient Sample data provided by the HIRA mainly focused on the pediatric population \[[@b20-kjp-2018-07290]\]. The data was extracted from claims for 1.4 million patients per year (3%), using gender- and age-stratified random sampling, and included the generic name, prescription date, dosage, duration, and route of administration of the drug. Diagnoses were recorded according to the International Classification of Diseases, Tenth Revision. The study population consisted of patients aged 2--17 years, for whom antibiotics were prescribed in the outpatient setting. In total, 129 systemic antibiotics that were coded as J01 (according to the WHO Anatomical Therapeutic Chemical classification system) were included. Antibiotics were grouped into 25 different classes according to their mode of action. The antibiotic rate was calculated by dividing the number of antibiotic prescriptions by the number of all outpatient prescriptions per year, categorized by age group. The frequency and percentage of antibiotic prescriptions were calculated for each antibiotic class. The defined daily dose was calculated for individual antibiotics. Between 2010 and 2014, in total, 7,261,176 antibiotic prescriptions were provided to 1,039,756 patients. Most of these prescriptions (91.2%) were for the treatment of respiratory illnesses. The most frequent primary diagnosis was acute upper respiratory infection (24.4%), followed by acute bronchitis (22.2%). The antibiotic prescription rate was the highest for patients aged 2--6 years, comprising 84.0% of all outpatient prescriptions for that age group in 2014. The antibiotic prescription rate for all pediatric patients increased from 34.8% in 2010 to 70.4% in 2014. Among drug classes, extended-spectrum penicillins were the most commonly prescribed; however, the proportion of prescriptions for the class remained constant at 40.0%--41.0% between 2010 and 2014 ([Fig. 5](#f5-kjp-2018-07290){ref-type="fig"}). Interestingly, the proportion of prescriptions for thirdgeneration cephalosporins increased from 6.6% in 2010 to 10.3% in 2014, resulting in a relative difference of 55.7% (95% confidence interval, 55.2--56.2), while the percentages of prescriptions for first- and second-generation cephalosporins decreased over the same period. Amoxicillin-clavulanate was the most commonly used drug, and its use increased by 9.0% between 2010 and 2014 ([Table 1](#t1-kjp-2018-07290){ref-type="table"}). Unlike a previous study, this study showed that amoxicillin-clavulanate was more commonly prescribed than amoxicillin, which is the first-line drug of choice for many community-acquired respiratory tract infections. The reason for the increased use of third-generation cephalosporins is unclear. A concurrent decline in second-generation cephalosporins suggests that this class of drugs has been replaced by third-generation cephalosporins, without any clear explanation. However, this change in the pattern of drug prescriptions for children may have led to changes in overall prescription patterns among all age groups in Korea during the previous decade.

Conclusions
===========

Clearly, antibiotic consumption among Korean children is considerably high. In addition to antibiotic-related issues, high rates of polypharmacy have been frequently observed in children. One study demonstrated a higher rate of polypharmacy in a pediatric population aged 1--9 years than in an older population (19.4% vs. 4.5% in 2002--2003, 12.3% vs. 3.3% in 2012--2013) \[[@b21-kjp-2018-07290]\]. However, there was a decreasing trend in the prevalence of polypharmacy, from 65.3% in 2002 to 46.6% in 2013, which likely reflects the policy-driven change since the early 2000s that stemmed from quality assessment and a drug utilization review by the HIRA service \[[@b7-kjp-2018-07290]\]. These government-driven policies have played a pivotal role in controlling antibiotic use in Korea in recent decades. However, coordinated efforts toward communication with and education of parents in order to address misunderstandings regarding antibiotic use, involving interprofessional antimicrobial stewardship programs, are required in the near future.
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###### 

Annual antibiotic prescription patterns by antibiotic class represented using the DDD per 1,000 inhabitants per day among pediatric outpatients in Korea in 2010--2014

  Individual antibiotics     DDD/1,000 patients/day   \% DDD   Annual DDD/1,000 patients/day                           
  -------------------------- ------------------------ -------- ------------------------------- ------- ------- ------- -------
  Penicillins                                                                                                          
   Amoxicillin               3.51                     2.4      3.51                            4.59    2.68    2.44    4.15
   Amoxicillin/clavulanate   67.40                    45.1     68.96                           94.62   49.01   44.03   75.26
  Macrolides                                                                                                           
   Clarithromycin            26.14                    17.50    25.03                           42.37   17.97   14.85   27.28
   Roxithromycin             5.46                     5.46     6.58                            7.91    3.81    3.44    4.77
  Cephalosporines                                                                                                      
   Cefaclor                  13.77                    9.2      16.03                           19.26   9.82    8.89    13.25
   Cefuroxime                3.73                     2.5      5.26                            5.38    2.31    1.98    3.01
   Cefpodoxime               16.78                    11.2     13.14                           22.23   12.57   10.72   25.82

DDD, defined daily dose.

Adapted from Song et al. Pediatr Int 2018;60:803-10. \[[@b20-kjp-2018-07290]\]
